Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab with chemotherapy may kill more cancer cells.

PURPOSE: Phase I trial to study the effectiveness of rituximab plus combination chemotherapy in treating patients who have HIV-related non-Hodgkin's lymphoma.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lymphoma Trials Office
• Treatments: Bleomycin; Prednisolone; Rituximab; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of poor-prognosis, HIV-related non-Hodgkin's lymphoma (HIV-NHL)

• Previously untreated

• More than 1 of the following criteria:

• Prior diagnosis of AIDS

• ECOG performance status 3-4

• CD4 count less than 100/mm3

• No primary cerebral lymphoma

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• See Disease Characteristics

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Not specified

Renal:

• Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• No prior chemotherapy for HIV-NHL

• At least 1 year since prior chemotherapy for Kaposi's sarcoma (KS)

Endocrine therapy:

• Not specified

Radiotherapy:

• Prior radiotherapy for HIV-NHL allowed

• At least 1 year since prior radiotherapy for KS

Surgery:

• Not specified